Drug
Prasterone (DHEA)
Prasterone (DHEA) is a pharmaceutical drug with 3 clinical trials. Historical success rate of 100.0%.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 1 completed trials
Completion Rate
100%(1/1)
Active Trials
0(0%)
Results Posted
100%(1 trials)
Phase Distribution
Ph phase_3
3
100%
Phase Distribution
0
Early Stage
0
Mid Stage
3
Late Stage
Phase Distribution3 total trials
Phase 3Large-scale testing
3(100.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
50.0%
1 of 2 finished
Non-Completion Rate
50.0%
1 ended early
Currently Active
0
trials recruiting
Total Trials
3
all time
Status Distribution
Active(1)
Completed(1)
Terminated(1)
Detailed Status
Completed1
Not yet recruiting1
Withdrawn1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
0
Success Rate
100.0%
Most Advanced
Phase 3
Trials by Phase
Phase 33 (100.0%)
Trials by Status
completed133%
not_yet_recruiting133%
withdrawn133%
Recent Activity
0 active trials
Showing 3 of 3
not_yet_recruitingphase_3
Effect of Intravaginal Prasterone on Symptoms of Genitourinary Syndrome of Menopause (GSM) in Women in Menopause With Previous Breast Cancer
NCT06611514
withdrawnphase_3
Effect of Intravaginal Prasterone on Symptoms of VVA in Women Under Treatment With an Aromatase Inhibitor for Breast Cancer
NCT03740945
completedphase_3
Intravaginal Prasterone (DHEA) Against Vulvovaginal Atrophy Associated With Menopause
NCT02013544
Clinical Trials (3)
Showing 3 of 3 trials
NCT06611514Phase 3
Effect of Intravaginal Prasterone on Symptoms of Genitourinary Syndrome of Menopause (GSM) in Women in Menopause With Previous Breast Cancer
NCT03740945Phase 3
Effect of Intravaginal Prasterone on Symptoms of VVA in Women Under Treatment With an Aromatase Inhibitor for Breast Cancer
NCT02013544Phase 3
Intravaginal Prasterone (DHEA) Against Vulvovaginal Atrophy Associated With Menopause
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3